Rilvegostomig + Chemo for 1st line treatment of patients with metastatic Non-squamous NSCLC with PDL1 expression

A Phase III, Randomized, Double-Blind, Multicenter, Global Study of Rilvegostomig in Combination with Chemotherapy for First-line Treatment of Patients with Metastatic Non-squamous Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)

Disease Types: Lung

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase III, Randomized, Double-Blind, Multicenter, Global Study of Rilvegostomig in Combination with Chemotherapy for First-line Treatment of Patients with Metastatic Non-squamous Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)

For More Information:

https://clinicaltrials.gov/study/NCT06627647?term=%20(ARTEMIDE-Lung03)&rank=1